 |
Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
22 May 2013
|
16.1 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice...
|
|
Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations
9 May 2013
|
111.6 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, May 9, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter ended March 31, 2013 and provided an update on compan...
|
|
Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
3 May 2013
|
15.9 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, May 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first ...
|
|
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
30 Apr 2013
|
17.9 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, April 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administr...
|
|
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
23 Apr 2013
|
66.7 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Food and Drug Administration (FDA) has accepted its Supplemental New Drug Application (...
|
|
Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
18 Apr 2013
|
17.8 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, April 18, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administr...
|
|
Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
8 Apr 2013
|
18.2 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, April 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today additional data from Amarin's previously announced MARINE and ANCHOR Phase 3 clinical trial resu...
|
|
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication
7 Mar 2013
|
61.2 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, March 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notic...
|
|
Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations
28 Feb 2013
|
85.6 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the quarter and year ended December 31, 2012 and provided an upd...
|
|
Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
26 Feb 2013
|
66.8 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has submitted a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Admi...
|
|
Amarin to Report Fourth Quarter and Year-End 2012 Results and Host Conference Call on February 28, 2013
22 Feb 2013
|
13.9 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the comp...
|
|
Amarin to Present at the CITI 2013 Global Healthcare Conference
21 Feb 2013
|
13.4 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer, is scheduled to present a gener...
|
|
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication
12 Feb 2013
|
16.0 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 12, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice o...
|
|
Amarin to Present at the Leerink Swann Global Healthcare Conference 2013
7 Feb 2013
|
13.4 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's President, is scheduled to present a general company update at the Leerink...
|
|
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication
7 Feb 2013
|
16.3 KB |
|
| |
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice o...
|
|
Amarin Announces Notification of Additional U.S. Patent Allowance for U.S. Application 13/272,520 Based on ANCHOR Clinical Trial Results
1 Feb 2013
|
63.5 KB |
|
| |
Patent Application Related to High (≥200 mg/dL to ...
|
|
Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication
31 Jan 2013
|
15.8 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notices ...
|
|
Amarin Announces Market Introduction of Vascepa(R) (icosapent ethyl) Capsules for the Treatment of Very High Triglycerides (VHTG)
24 Jan 2013
|
89.8 KB |
|
| |
-First and Only FDA Approved Pure-EPA Omega-3 Prescription Therapy Now Available-
-Vascepa Reduces VHTG Without Raising LDL Cholesterol-
...
|
|
Amarin Announces First Notification of U.S. Patent Allowance Based on ANCHOR Clinical Trial Results
23 Jan 2013
|
16.7 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice...
|
|
Amarin Announces Publication of Additional Inflammatory Marker Data From MARINE and ANCHOR Phase 3 Clinical Trials in the American Journal of Cardiovascular Drugs
22 Jan 2013
|
16.6 KB |
|
| |
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that additional data from its pivotal MARINE and ANCHOR Phase 3 clinical trials are now available...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter